Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 3.32% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 3.32% | |
| NR7 | Range Contraction | 3.32% | |
| NR7-2 | Range Contraction | 3.32% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 4.87% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.87% | |
| NR7 | Range Contraction | 4.87% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.84% | |
| Calm After Storm | Range Contraction | 0.84% | |
| Inside Day | Range Contraction | 0.84% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 8 minutes ago |
| Rose Above 10 DMA | 8 minutes ago |
| Up 1% | 8 minutes ago |
| Up 1% | about 21 hours ago |
| Non-ADX 1,2,3,4 Pullback Entry | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/31/2024
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Disease Clinical Development Lupus Peptides Nephrology Immunosuppressants Lupus Nephritis Nephritis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Disease Clinical Development Lupus Peptides Nephrology Immunosuppressants Lupus Nephritis Nephritis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.725 |
| 52 Week Low | 4.71 |
| Average Volume | 1,148,996 |
| 200-Day Moving Average | 6.08 |
| 50-Day Moving Average | 7.35 |
| 20-Day Moving Average | 7.77 |
| 10-Day Moving Average | 8.26 |
| Average True Range | 0.32 |
| RSI (14) | 63.90 |
| ADX | 31.03 |
| +DI | 29.66 |
| -DI | 14.26 |
| Chandelier Exit (Long, 3 ATRs) | 7.79 |
| Chandelier Exit (Short, 3 ATRs) | 7.80 |
| Upper Bollinger Bands | 8.80 |
| Lower Bollinger Band | 6.74 |
| Percent B (%b) | 0.73 |
| BandWidth | 26.49 |
| MACD Line | 0.30 |
| MACD Signal Line | 0.29 |
| MACD Histogram | 0.0128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.77 | ||||
| Resistance 3 (R3) | 8.71 | 8.49 | 8.68 | ||
| Resistance 2 (R2) | 8.49 | 8.35 | 8.51 | 8.65 | |
| Resistance 1 (R1) | 8.36 | 8.27 | 8.43 | 8.42 | 8.62 |
| Pivot Point | 8.14 | 8.14 | 8.17 | 8.16 | 8.14 |
| Support 1 (S1) | 8.01 | 8.00 | 8.08 | 8.07 | 7.86 |
| Support 2 (S2) | 7.79 | 7.92 | 7.81 | 7.83 | |
| Support 3 (S3) | 7.66 | 7.79 | 7.80 | ||
| Support 4 (S4) | 7.72 |
